Anti–Placental Growth Factor Reduces Bone Metastasis by Blocking Tumor Cell Engraftment and Osteoclast Differentiation
- 14 August 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (16), 6537-6547
- https://doi.org/10.1158/0008-5472.can-09-4092
Abstract
Treatment of bone metastases is largely symptomatic and is still an unmet medical need. Current therapies mainly target the late phase of tumor-induced osteoclast activation and hereby inhibit further metastatic growth. This treatment method is, however, less effective in preventing initial tumor engraftment, a process that is supposed to depend on the bone microenvironment. We explored whether bone-derived placental growth factor (PlGF), a homologue of vascular endothelial growth factor-A, regulates osteolytic metastasis. Osteogenic cells secrete PlGF, the expression of which is enhanced by bone-metastasizing breast tumor cells. Selective neutralization of host-derived PlGF by anti-mouse PlGF (αPlGF) reduced the incidence, number, and size of bone metastases, and preserved bone mass. αPlGF did not affect metastatic tumor angiogenesis but inhibited osteoclast formation by preventing the upregulation of the osteoclastogenic cytokine receptor activator of NF-κB ligand in osteogenic cells, as well as by blocking the autocrine osteoclastogenic activity of PlGF. αPlGF also reduced the engraftment of tumor cells in the bone and inhibited their interaction with matrix components in the metastatic niche. αPlGF therefore inhibits not only the progression of metastasis but also the settlement of tumor in the bone. These findings identify novel properties of PlGF and suggest that αPlGF might offer opportunities for adjuvant therapy of bone metastasis. Cancer Res; 70(16); 6537–47. ©2010 AACR.Keywords
Other Versions
This publication has 49 references indexed in Scilit:
- VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis FormationPLOS ONE, 2009
- Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival SignalsCancer Cell, 2009
- FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nature Reviews Cancer, 2008
- Inhibition of Metastatic Outgrowth from Single Dormant Tumor Cells by Targeting the CytoskeletonCancer Research, 2008
- Risks and benefits of bisphosphonatesBritish Journal of Cancer, 2008
- Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblastsJCI Insight, 2006
- Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repairJCI Insight, 2006
- Placenta growth factor is over-expressed and has prognostic value in human breast cancerEuropean Journal of Cancer, 2005
- Vascular endothelial growth factor receptors in osteoclast differentiation and functionBiochemical and Biophysical Research Communications, 2005
- A Pooled Analysis of Bone Marrow Micrometastasis in Breast CancerNew England Journal of Medicine, 2005